| Value | ₹1,500 Cr |
|---|
BSE filing, NSE: CANBK. Summary written from the filing by ALFA Finder's alert engine.
Canara Bank: key numbers
- Share price
- ₹117.82
- Market cap
- ₹1,06,870 Cr
- Revenue (annual)
- ₹1,26,371 Cr
- Net profit (annual)
- ₹17,873 Cr
- P/E (TTM)
- 5.2×Sector 19.7×
- Promoter holding
- 62.93%+0.00% QoQ
- FII holding
- 12.27%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Canara Bank
All →Canara Bank Debt & Borrowing: ₹1,500 Cr
Canara Bank fully redeemed Basel III AT1 bonds via call option on 23-Oct-2026, amounting to Rs. 1,500 Crore. Redemption was made ahead of the 25-Oct-2026 due date.
- Value
- ₹1,500 Cr
Canara Bank Debt & Borrowing: ₹126 Cr
Canara Bank paid Rs.126.00 Crore interest on its Basel III Additional Tier I bonds (ISIN INE476A08126) on 23 October 2026, at 8.4% on Rs.1,500 Crore issue size. No delay or non-payment was reported.
- Value
- ₹126.0 Cr
Canara Bank Debt & Borrowing: ₹1,626 Cr
Canara Bank paid Rs.1,626 Crore, covering full redemption and annual interest, on its AT1 bonds on October 23, 2026. The bonds are now fully redeemed.
- Value
- ₹1,626 Cr
Canara Bank Earnings Call Transcript: Key Takeaways
Canara Bank delivered a record performance in Q2 FY27, crossing ₹30 lakh crore business milestone with ever-highest quarterly net profit. Strategy focuses on sustainable growth across RAM segments and maintaining robust asset quality.
Canara Bank Other Announcement
Canara Bank filed its quarterly Security Cover Certificate for Q3 FY27 under Reg 54. All listed NCDs are unsecured with Nil cover/assets required, making this routine compliance paperwork.
Canara Bank Results Update
Canara Bank's Q2 FY27 press release reports 8.40% YoY profit growth and GNPAs improving to 1.33%. Business grew 15.88% with retail credit up 31.61%.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
KFIN Technologies Regulatory Approval
KFin Technologies' Thai subsidiary received a Foreign Business License from Thailand's Ministry of Commerce. The license enables the subsidiary to conduct permitted business activities under local law.